| Firm | Analyst | Phone | Type | Rating | |
|---|---|---|---|---|---|
|
B. Riley Securities
|
Mayank Mamtani | ||||
|
Baird
|
Colleen M. Kusy, CFA | ||||
|
BTIG
|
Julian Harrison | ||||
|
Chardan
|
Geulah Livshits, Ph.D. | ||||
|
H.C. Wainwright & Co.
|
Raghuram Selvaraju, Ph.D., M.B.A. & Mitchell Kapoor | ||||
|
Leerink Partners
|
Thomas J. Smith | ||||
|
Mizuho
|
Joseph Catanzaro | ||||
|
Oppenheimer & Co. Inc.
|
Leland Gershell, MD, Ph.D. | ||||
|
Piper Sandler
|
Yasmeen Rahimi, Ph.D | ||||
|
Raymond James
|
Chris Raymond | ||||
|
Truist Securities
|
Danielle Brill, Pharm.D. | ||||
|
Wedbush Securities
|
Laura Chico, Ph.D. | ||||
|
William Blair
|
Matt Phipps, Ph.D. |
Climb Bio is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Climb Bio's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Climb Bio or its management. Climb Bio does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.